A class-action lawsuit has been filed against CVS Caremark over its decision to stop covering Zepbound, Eli Lilly’s blockbuster GLP-1 drug to treat obesity.

When the major pharmacy benefit manager informed patients about the change this year , it suggested that there was “another covered medication that’s safe and effective for your condition and may cost less”: namely Wegovy, from Novo Nordisk, with which CVS Caremark announced a partnership just before the change took effect.

But many patients and their doctors say the treatments aren’t medically interchangeable.

John Cole, who lives in the Midwest, says he lost more than 60 pounds over the course of about five months while using Zepbound. Letters from his family medicine doctor, cardiologist and rheumatologist all indicate that h

See Full Page